Potential New Drug and Clinical Trial: Sarcoidosis Goes “Modern” with Crowdsourcing
Developing new drugs for the treatment of sarcoidosis isn’t easy. First, the cause of sarcoidosis is unknown. Second, prednisone, a remarkably effective medication for the treatment of sarcoidosis, limited only by its adverse side effect profile, is tough to beat. Third, sarcoidosis is a rare disease, which affects fewer than 200,000 people in the US per year. These challenges notwithstanding, researchers at Mount Sinai will be testing a new drug for the treatment of sarcoidosis. In late 2015, the Division of Pulmonary, Critical Care and Sleep Medicine will be enrolling sarcoidosis patients, who meet prespecified entry criteria, into a clinical trial to evaluate the efficacy and safety of KiactaTM for the treatment of sarcoidosis.
